このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

安定化レチナールの加齢肌への影響:スプリットフェイス研究

2026年11月10日 更新者:Medical University of Silesia

0.1%および0.05%の安定化レチナールデヒドの局所塗布により誘発される加齢肌の構造的・光学的変化の多角的評価:24週間スプリットフェイス試験

The goal of this clinical trial is to learn if retinaldehyde cream improves the appearance of aging skin in women aged 30 to 60 years. Retinaldehyde is a form of vitamin A that the skin can convert into retinoic acid, which is known to help with skin aging. The study tested two strengths of retinaldehyde cream: a stronger version with 0.1% retinaldehyde and a weaker version with 0.05% retinaldehyde.

The main questions the study aimed to answer were: whether retinaldehyde cream improves skin hydration and reduces oiliness, whether it improves skin firmness and elasticity, whether it reduces wrinkles and improves skin texture, whether it reduces uneven skin tone and pigmentation, and whether the stronger 0.1% cream works better than the weaker 0.05% cream.

Researchers compared the two cream strengths by applying them to opposite sides of the same face. The stronger 0.1% cream was applied to the left side and the weaker 0.05% cream was applied to the right side. This approach allowed researchers to compare the two strengths directly in the same person under the same conditions.

56 women with visible signs of aging skin took part in the study at the Medical University of Silesia in Poland. One participant left the study early due to skin irritation. The remaining 55 women completed all 24 weeks of the study.

Participants apply the creams in the evening, starting with twice a week for the first 2 weeks, then increasing to 3 times a week in week 3 and 4 times a week in week 4, based on skin tolerance, for 24 weeks total. They also used a provided skincare routine every day, which included a lipid face cream, a cleansing lotion, and a sunscreen with SPF 50 to protect their skin during the study.

Participants were assessed 3 times: before starting the creams, after 12 weeks of use, and after 24 weeks of use. At each visit, researchers measured skin hydration, oiliness, elasticity, firmness, wrinkle depth, skin density, skin color, and other skin properties using a range of specialized skin measurement tools. Neither the participants nor the researchers assessing outcomes knew which cream strength was applied to which side of the face.

調査の概要

状態

完了

条件

介入・治療

詳細な説明

This study investigated the effects of topically applied stabilized retinaldehyde (RAL) at two concentrations (0.1% and 0.05%) on aging skin in 56 women (55 completing the study) aged 30-60 years (mean age 44.25 ± 8.1 years) with visible signs of photoaging including fine lines, wrinkles, pigmentation disorders, seborrhea, and loss of skin firmness.

A 24-week, double-blind, split-face design was employed. The 0.1% RAL formulation was applied to the left side of the face and the 0.05% formulation to the right side. Application frequency started with twice weekly for the first 2 weeks, increasing to three times per week in week 3 and four times per week in week 4, based on skin tolerance. Both formulations contained stabilized retinaldehyde encapsulated in a cyclodextrin-glycosaminoglycan complex to enhance stability and provide controlled transdermal delivery. The tested products were commercially available formulations provided by the study collaborator. All participants followed a standardized background skincare regimen consisting of a lipid cream, cleansing lotion, and SPF 50 sunscreen throughout the study period.

Skin assessments were performed at baseline (T0), after 12 weeks (T1), and after 24 weeks (T2) using a multimodal diagnostic approach at the Department of Basic Biomedical Sciences, Faculty of Pharmaceutical Sciences, Medical University of Silesia.

Biophysical measurements included stratum corneum hydration (Corneometer CM 825), sebum excretion rate (Sebumeter SM 815), and melanin and erythema indices (Mexameter MX 18). Structural assessments were performed using high-frequency ultrasound (DUB SkinScanner, 50 MHz) to evaluate skin density and epidermal thickness, and the Cutometer MPA 580 to assess skin viscoelasticity and elasticity parameters (R2, R5, R7, Q1, Q2). Wrinkle depth and surface parameters were evaluated using Antera 3D imaging. Optical and imaging assessments included colorimetric analysis of L*, a*, and b* values (Antera 3D), hyperspectral imaging across 400-1000 nm spectral range (SPECIM IQ), and Gray Level Co-Occurrence Matrix (GLCM) texture analysis including contrast and homogeneity of standardized clinical photographs (Fotomedicus system).

The study aimed to determine whether stabilized RAL induces measurable structural, vascular, spectral, and optical changes in aging skin, and to compare the dose-dependent efficacy of 0.1% versus 0.05% concentrations across all measured parameters.

One participant withdrew from the study due to facial erythema and discomfort. No other serious adverse events were reported.

研究の種類

介入

入学 (実際)

56

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Sosnowiec、ポーランド、41-205
        • Department of Basic Biomedical Science, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Sosnowiec, Poland

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

30年~60年 (大人)

健康ボランティアの受け入れ

はい

受講資格のある性別

女性

説明

Inclusion Criteria:

  • Age 30-60 years
  • Presence of wrinkles, dark spots, acne, seborrhea
  • Decreased skin firmness

Exclusion Criteria:

  • Exacerbated active atopic dermatitis on the face
  • Pregnancy
  • Skin infections
  • Numerous erosions or excoriations on facial skin
  • No aesthetic medical treatments within the preceding 6 months
  • Administration of botulinum toxin within the preceding 3 months
  • Irritated, dry skin
  • Irritated or excessively dry skin

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Retinaldehyde 0.1% (Left Side)

Stabilized retinaldehyde 0.1% formulation applied to the left side of the face for 24 weeks. Application frequency started with twice weekly for the first 2 weeks, increasing to three times per week in week 3 and four times per week in week 4, based on skin tolerance.

Stabilized retinaldehyde 0.1% encapsulated in a cyclodextrin-glycosaminoglycan complex, formulated as a topical cosmetic cream, applied to the left side of the face. Application frequency started with twice weekly for the first 2 weeks, increasing to three times per week in week 3 and four times per week in week 4, based on skin tolerance, for a total of 24 weeks.

他の名前:
  • 網膜 0.1%
実験的:Retinaldehyde 0.05% (Right Side)

Stabilized retinaldehyde 0.05% formulation applied to the right side of the face for 24 weeks. Application frequency started with twice weekly for the first 2 weeks, increasing to three times per week in week 3 and four times per week in week 4, based on skin tolerance.

Stabilized retinaldehyde 0.05% encapsulated in a cyclodextrin-glycosaminoglycan complex, formulated as a topical cosmetic cream, applied to the right side of the face. Application frequency started with twice weekly for the first 2 weeks, increasing to three times per week in week 3 and four times per week in week 4, based on skin tolerance, for a total of 24 weeks.

他の名前:
  • 網膜0.05%

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Skin Hydration
時間枠:Baseline and 24 weeks

Stratum corneum hydration measured using Corneometer CM 825 (Courage+Khazaka, Germany). Three consecutive measurements taken at predefined anatomical landmarks on both sides of the face.

Baseline and 24 weeks
Sebum Excretion Rate
時間枠:Baseline and 24 weeks

Sebum levels measured using Sebumeter SM 815 (Courage+Khazaka, Germany). Single measurement at each predefined anatomical site applied with constant pressure of 10 N for 30 seconds.

Baseline and 24 weeks
Melanin Index
時間枠:Baseline and 24 weeks

Melanin content measured using Mexameter MX 18 (Courage+Khazaka, Germany). Three consecutive measurements taken at predefined anatomical landmarks.

Baseline and 24 weeks
Erythema Index
時間枠:Baseline and 24 weeks

Erythema measured using Mexameter MX 18 (Courage+Khazaka, Germany). Three consecutive measurements taken at predefined anatomical landmarks.

Baseline and 24 weeks
Skin Density and Epidermal Thickness
時間枠:Baseline and 24 weeks

Assessed using high-frequency ultrasound DUB SkinScanner 50 MHz. Skin density measured using ROI function directly beneath epidermis. Epidermal thickness calculated in millimeters based on A-scan.

Baseline and 24 weeks
Skin Viscoelasticity and Elasticity
時間枠:Baseline and 24 weeks

Assessed using Cutometer MPA 580 (Courage+Khazaka, Germany) with 2 mm probe. Parameters R2, R5, R7, Q1, Q2 extracted from deformation curves.

Baseline and 24 weeks
Wrinkle Depth and Surface Parameters
時間枠:Baseline and 24 weeks

Assessed using Antera 3D imaging system (Miravex Limited, Ireland) with multi-directional illumination. ROIs of 20x20 mm at predefined anatomical landmarks.

Baseline and 24 weeks
Colorimetric Parameters
時間枠:Baseline and 24 weeks

L*, a*, b* values measured using Antera 3D imaging system (Miravex Limited, Ireland). Data extracted from standardized ROIs of 20x20 mm.

Baseline and 24 weeks
Skin Texture - GLCM Analysis
時間枠:Baseline and 24 weeks

Contrast and homogeneity assessed using Gray Level Co-Occurrence Matrix (GLCM) analysis of standardized clinical photographs taken with Fotomedicus system (Elfo, Poland). ROIs of 200x200 pixels extracted from central cheek coordinates.

Baseline and 24 weeks
Hyperspectral Imaging
時間枠:Baseline and 24 weeks

Reflectance and hemoglobin variability assessed using SPECIM IQ hyperspectral camera (Specim, Finland), spectral range 400-1000 nm, spectral resolution 5 nm. ROIs of 100x100 pixels from predefined cheek coordinates.

Baseline and 24 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • 主任研究者:Sławomir Wilczyński, Prof. PhD、Department of Basic Biomedical Science, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Sosnowiec, Poland

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年2月1日

一次修了 (実際)

2023年7月31日

研究の完了 (実際)

2023年7月31日

試験登録日

最初に提出

2026年3月26日

QC基準を満たした最初の提出物

2026年3月26日

最初の投稿 (実際)

2026年4月3日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月16日

QC基準を満たした最後の更新が送信されました

2026年11月10日

最終確認日

2026年3月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • PCN/CBN/0022/KB1/27

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

De-identified individual participant data underlying the results reported in publications will be shared upon reasonable request. This includes data necessary to reproduce the findings presented in the articles. Data will be available after publication, subject to institutional policies, ethical approval, and applicable data protection regulations. No directly identifiable data will be shared. Supporting documents such as the study protocol and statistical analysis plan may also be made available upon request.

IPD 共有時間枠

Data will be available beginning 3 months after publication of the final study results and will remain available for 5 years.

IPD 共有アクセス基準

Access to de-identified individual participant data will be provided to qualified researchers upon reasonable request. Requests should include a brief description of the research purpose. Requests will be reviewed by the study investigators. Data will be shared in accordance with institutional policies, ethical considerations, and applicable data protection regulations.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。